Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J's Risperdal "Not Approvable" In Alzheimer's Psychosis

This article was originally published in The Pink Sheet Daily

Executive Summary

The company issues its second announcement in a week that Risperdal has been deemed not approvable for a supplemental indication; FDA also issued a not approvable letter for risperidone for the treatment of autism.

You may also be interested in...



Forest’s Namenda Gets “Not Approvable” Letter For Mild Alzheimer’s Indication

The firm blames supplementary studies – which found numerical improvement for the memantine cohort but failed to meet statistical significance – for the denial.

Forest’s Namenda Gets “Not Approvable” Letter For Mild Alzheimer’s Indication

The firm blames supplementary studies – which found numerical improvement for the memantine cohort but failed to meet statistical significance – for the denial.

J&J's Risperdal "Not Approvable" For Autism

FDA issues a "not approvable" letter for risperidone, despite the agency's mid-2004 determination that the antipsychotic was "approvable" for autism. J&J is considering the "appropriate next steps" for the indication.

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel